Technology Appraisal Virtual Committee Meeting

Committee C

### Minutes: Confirmed

### Date and Time: Tuesday 1 September 2020

### Present:

* Alex Cale Present for all notes
* Michael Chambers Present for all notes
* Prithwiraj Das Present for all notes
* David Foreman Present for all notes
* Rob Forsyth Present for all notes
* Natalie Hallas Present for all notes
* Nigel Langford Present for all notes
* Andrea Manca Present for notes 1-9 & 18- 24
* Iain McGowan Present for all notes
* Kirandip Moyo Present for notes 1 to 17
* Mudasar Mushtaq Present or notes 1 to 17
* Richard Nicholas Present for notes 10 to 24
* Ugochi Nwulu Present for all notes
* Stella O'Brien Present for all notes
* Stephen O’Brien (C) Present for all notes
* Subhash Pokhrel Present for all notes
* Andrew Renehan Present for all notes
* Lindsay Smith (C) Present for notes 18 to 24
* Matthew Stevenson Present for notes
* Paul Tappenden Present for notes 1 to 9 & 18 to 24

### NICE Staff In attendance:

* Jasdeep Hayre, Associate Director, NICE, Present for notes 10 to 24
* Linda Landalls, Associate Director, NICE, Present for notes 1 to 9
* Gavin Kenny, Project Manager, NICE, Present for all notes
* Kate Moore, Project Manager, NICE, Present for all notes
* Jamie Elvidge, Technical Adviser, NICE, Present for notes 1 to 9 & 18 to 24
* Nicola Hay, Technical Adviser, NICE, Present for notes 10 to 17
* Zain Hussain, Technical Analyst, NICE, Present for notes 1 to 9
* Thomas Paling, Technical Analyst, NICE, Present for notes 10 to 17
* Catherine Pank, Corporate Office Coordinator, NICE, Present for notes 1 to 5 & 10 to 14
* Sandra Robinson, Corporate Office Coordinator, NICE, Present for notes 1 to 5 & 10 to 14
* Gemma Smith, Committee Operations Coordinator, NICE, Present for all notes
* Mandy Tonkinson, Public Involvement Adviser, NICE. Present for notes 1 to 5 & 10 to 14
* Ismahan Abdullah, Technology Appraisals Administrator, NICE, Present for notes 1 to 9
* Celia Mayers, Technology Appraisals Administrator, NICE Present for all notes

## ERG Representatives in attendance:

* James Mahon, LRIG, Evidence Review Group, Present for notes 1 to 5
* Sarah Nevitt, LRIG, Evidence Review Group, Present for notes 1 to 5
* Kate Ennis, ScHARR, Evidence Review Group, Present for notes 10 to 14
* Paul Tappenden, ScHARR Group, Evidence Review Group, Present for notes 10 to 14

## Clinical & Patient experts in attendance:

* Aisha Ali, Commissioning Expert, Present for notes 10 to 14
* Professor Peter Clark, Cancer drugs Fund Clinical Lead, Present for notes 1 to 9
* Dr Steven Knapper, Clinical Expert, Clinical Reader in Haematology and Honorary Consultant Haematologist, Cardiff University Present for notes 1 to 5
* Dr Deepti Radia, Clinical Expert, Consultant Haematologist, Guys and St Thomas Trust, Present for notes 1 to 5
* Philip Hawkins, Clinical Expert, Job Title, Present for notes 10 to 14
* Marianna Fontana, Clinical Expert, Associate Professor Honorary Consultant Cardiologist, UCL, Present for notes 10 to 14
* Perry Elliott, Clinical Expert, Professor of Cardiovascular Medicine and Consultant Cardiologist, University College London and Bart’s Heart Centre, Present for notes 10 to 14
* Andrew Dugdale, Patient Expert, Trustee, The UK Mastocytosis Support Group, Present for notes 1 to 5
* Jess Hobart, Patient Expert, Chair of Trustees, The UK Mastocytosis Support Group, Present for notes 1 to 5
* David Gregory, Patient Expert, Trustee, UK ATTR Amyloidosis Patients Association (UKATPA), Present for notes 10 to 14
* Ken Lumley, Patient Expert, Present for notes 10 to 14
* Vincent Nicholas, Patient Expert, Trustee, UK ATTR Amyloidosis Patients’ Association (UKATPA), Present for notes 10 to 14
* Paul Pozzo, Patient Expert, Present for notes 10 to 14

## Other Non-public attendees:

* Emilene Coventry, Senior Medical Editor, NICE, Present for notes 1 to 9
* Ann Greenwood, Senior Medical Editor, NICE, Present for notes 10 to 17
* Henry Edwards, HTA Adviser, NICE, Present for notes 10 to 17

### Appraisal of Midostaurin for treating advanced systemic mastocytosis [ID1573]

### Part 1 – Open session

1. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG) representatives and representatives from Novartis.
2. The Chair asked all committee members, experts, ERG representatives and NICE staff present to declare any relevant interests:  
   1. Michael Chambers declared a financial interest as he is currently helping to co-ordinate a training programme on Real World Evidence for Roche pharmaceuticals however this has not involved specific consideration of any Roche products.
      1. It was agreed that this declaration would not prevent Michael from participating in discussion on this topic.
   2. Prithwiraj Das declared a non-financial & personal Interest as he works at Boehringer Ingelheim Ltd as the Market Access Lead on Specialty Medicines (oncology, inflammation, thrombolysis). However, he has not worked on any of these indications in the last 12 months.
      1. It was agreed that this declaration would not prevent Prithwiraj from participating in discussions on this topic.
   3. Jess Hobart declared indirect interests due to the Novartis contract agreed for up to £10,000 for collaborative project on the patient experience in 2019/2020 (though at this time no payments have been received on this contract) Novartis also paid an honorarium of £750 for a talk Jess gave at the EAACI meeting in June, 2019 about mastocytosis. The honorarium was paid directly to the charity.
      1. It was agreed that this declaration would not prevent Jess from participating in part 1 discussions on this topic.
   4. Andrew Dugdale declared Direct and Indirect interests due to the Novartis contract agreed for up to £10,000 for collaborative project on the patient experience in 2019/2020 (though at this time no payments have been received on this contract) with The UK Mastocytosis Support Group. He also received an honorarium of £750 from Novartis to speak at a symposiums on mastocytosis at the EAACI conference in June, 2019. Andrew stated he is carrying out work for the contract agreed between The UK Mastocytosis Support Group and Novartis for 2019/2020. He has not yet received payment for this work, but we expect that he will in future (while some of the money will also go to the charity).
      1. It was agreed that this declaration would not prevent Andrew from participating in part 1 discussions on this topic.
   5. Deepti Radia declared Direct Financial and Non-Financial interests as he has received payments for speaking engagements and sitting on advisory boards for Novartis – educational events presenting on systemic mastocytosis, He has also been actively involved with the UKMasto patient support group – educational events, providing updates and also clinical advice if needed. He has also been invited to represent the BSH – as haematologist with expertise in this area for the NICE appraisal in January 2020. Deepti also stated he is a member of the UK MPN NCRI group and report on SM initiatives.
      1. It was agreed that this declaration would not prevent Deepti from participating in part 1 discussions on this topic.
   6. Steven Knapper declared Direct Financial interests as within the last 12 months he has received honoraria from Novartis for 2 speaker meetings which have included some discussion of midostaurin use in acute myeloid leukaemia (but not mastocytosis) he has also received laboratory research funding (to Cardiff University) from Novartis relating to genetic mutational screening in acute myeloid leukaemia (not relating to mastocytosis)
      1. It was agreed that this declaration would not prevent Steven from participating in part 1 discussions on this topic.
3. No further conflicts of interest were declared for this appraisal.
4. The Chair introduced the lead team who gave presentations on the clinical effectiveness and cost effectiveness of the treatment.
5. The Chair asked the company representatives whether they wished to comment on any matters of factual inaccuracy.

**Part 2 – Closed session (company representatives, clinical and patient experts, ERG/AG representatives and members of the public were asked to leave the meeting)**

1. The committee discussed confidential information submitted as part of this appraisal.
2. Agreement on the content of the Appraisal Consultation Document (ACD) was discussed by the committee.
3. The committee decision was based on consensus.
4. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

## Appraisal of Tafamidis for treating transthyretin amyloid cardiomyopathy (ID1531)

### Part 1 – Open session

1. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG) representatives and representatives from Pfizer.
2. The Chair asked all committee members, experts, ERG representatives and NICE staff present to declare any relevant interests  
   1. Prithwiraj Das declared a non-financial & personal Interest as he works at Boehringer Ingelheim as the Market Access Lead on Speciality Medicines (oncology, inflammation, thrombolysis). However, he has not worked on any of these indications in the last 12 months.
      1. It was agreed that this declaration would not prevent Prithwiraj from participating in this section of the meeting.
      2. Matt Stevenson declared a non-financial & personal Interest as he commented on the draft report for Tafamidis.
      3. It was agreed that this declaration would not prevent Matt from participating in this section of the meeting, however it was noted that he will not have a vote on the outcome if this topic.
3. No further conflicts of interest were declared for this appraisal.
4. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.
5. The Chair asked the company representatives whether they wished to comment on any matters of factual inaccuracy.

**Part 2 – Closed session (company representatives, clinical and patient experts, ERG/AG representatives and members of the public were asked to leave the meeting)**

1. Agreement on the content of the Final Appraisal Determination (FAD) was discussed by the committee.
2. The committee decision was based on consensus.
3. The committee asked the NICE technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

## Appraisal of Pembrolizumab for untreated metastatic or unresectable recurrent squamous cell head and neck cancer (ID1140)

### Part 1 – Open session

1. The Chair welcomed the Committee Members and NICE Staff to the meeting.
2. The Chair asked all committee members and NICE staff present to declare any relevant interests  
   1. Prithwiraj Das declared a non-financial & personal Interest as he works at Boehringer Ingelheim as the Market Access Lead on Specialty Medicines (oncology, inflammation, thrombolysis). However, he has not worked on any of these indications in the last 12 months.
      1. It was agreed that this declaration would not prevent Prithwiraj from participating in this section of the meeting
3. No further conflicts of interest were declared for this appraisal.
4. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.
5. Agreement on the content of the Final Appraisal Determination (FAD) was discussed by the committee.
6. The committee decision was based on consensus
7. The committee asked the NICE technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.